LEChENIE TRIZhDY NEGATIVNOGO RAKA MOLOChNOY ZhELEZY


Cite item

Full Text

Abstract

При постановке диагноза рака молочной железы (РМЖ) опухоль тестируется и классифицируется на основании наличия эстроген-, прогестерон- и HER2-рецепторов. В некоторых случаях опухоль негативна по всем трем рецепторам, в связи с чем данный подтип рака часто называют трижды негативным РМЖ. Это крайне агрессивная форма опухоли, характеризующаяся высоким уровнем метастазирования и низкой выживаемостью по сравнению с другими подтипами РМЖ. В отношении трижды негативного РМЖ не существует единого стандарта лечения. Несмотря на плохой прогноз, трижды негативный РМЖ чувствителен к стандартным химиотерапевтическим схемам, включая антрациклин- и таксансодержащие схемы, однако некоторые пациентки не отвечают на стандартную терапию. В настоящее время изучаются альтернативные химиотерапевтические препараты, такие как соединения платины, ингибиторы топоизомеразы, антиангиогенные и др., в неоадъювантном, адъювантном и лечебном режимах.

References

  1. Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005;116:340-50.
  2. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004;203:661-71.
  3. Anders C, Carey LA. Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 2008;22:1233-39.
  4. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. Jama 2006;295:1658-67.
  5. Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers? Int J Cancer 2008;123:236-40.
  6. Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol 2005;23:7350-60.
  7. Callagy G, Cattaneo E, Daigo Y, et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 2003;12:27-34.
  8. Carey L, Dees E, Sawyer L, et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34.
  9. Carey L, Perou C, Livasy C, et al. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA 2006;295:2492-02.
  10. Cleator S, Heller W, Coombes R. Triple-negative breast cancer: Therapeutic options. Lancet Oncol 2007;3:235-44.
  11. Dean-Colomb W, Yan K, Liedtke C, et al. Transcriptional profiles of triple receptor-negative breast cancer: Are Caucasian, Hispanic, and African-American women different (abstract 22014)? J Clin Oncol 2008;26(15S):750s.
  12. Demicheli R, Miceli R, Brambilla C, et al. Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of'cures'. Breast Cancer Res Treat 1999;53:209-15.
  13. Early Breast Cancer Trialists' Collaborative Group E. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
  14. Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004;64:830-35.
  15. Gonzalez-Angulo AM, et. Hortobagyi GN. Triple-Receptor-Negative Breast Cancer: What We Know and Issues to Be Resolved. Oncology 2008;22(11).
  16. Hayes N, Thor A, Dressler L, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007;357:1496-506.
  17. Ihemelandu CU, Lefall LD, Dewitty RL, et al. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: Age-specific prevalence and survival. J Surg Res 2007;143:109-18.
  18. Jacquemier J, Ginestier C, Rougemont J, et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 2005;65:767-79.
  19. Korsching E, Packeisen J, Agelopoulos K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002;82:1525-33.
  20. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007;9:R65.
  21. Liedtke C, Mazouni C, Hess K, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
  22. Menard S, Casalini P, Tomasic G, et al. Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Res Treat 1999;55:169-77.
  23. Millikan RC, Newman B, Tse C-K, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008;109:123-39.
  24. Nielsen T, Hsu F, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
  25. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
  26. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature 200;406:747-52.
  27. Rouzier R, Perou C, Symmans W, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85.
  28. Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008;68:3108-14.
  29. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
  30. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23.
  31. Sorlie T. Molecular portraits of breast cancer: Tumour subtypes as distinct disease entities. Eur J Cancer 2004;40:2667-75.
  32. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003;100:10393-98.
  33. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, et al. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 2000;18:4053-59.
  34. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003;9:568-74.
  35. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-19.
  36. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-96.
  37. Weigelt B, Glas AM, Wessels LF, et al. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA 2003;100:15901-05.
  38. Yang X, Sherman M, Rimm D, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007;16:439-43.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies